Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
164.3 USD | +0.33% | +2.45% | +6.04% |
May. 15 | Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM | |
May. 15 | Medincell: share price falls after disappointing clinical study | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.94 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.04% | 290B | C+ | ||
+32.36% | 694B | C+ | ||
+30.00% | 593B | B | ||
-1.60% | 371B | C+ | ||
+20.07% | 331B | B- | ||
+14.35% | 239B | B+ | ||
+10.31% | 209B | B- | ||
-3.27% | 209B | A+ | ||
+9.27% | 169B | C+ | ||
+0.45% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- Ratings AbbVie Inc.